Full Press Release Details
latest odronextamab data in relapsed refractory follicular lymphoma showed compelling responses and overall maintenance of patient reported outcomes.
REGN
latest odronextamab data in relapsed refractory follicular lymphoma showed compelling responses and overall maintenance of patient reported outcomes
Key Takeaway: latest odronextamab data in relapsed refractory follicular lymphoma showed compelling responses and overall maintenance of patient reported outcomes